Drug intelligence / Profile preview

VK3019

Development stage: Phase 1
Lead developer: Viking Therapeutics
Modality: Peptides
Administration: Subcutaneous

Overview

VK3019 is a novel amylin receptor agonist being developed by Viking Therapeutics for the treatment of obesity and related metabolic disorders. Amylin is a peptide hormone co-secreted with insulin that plays a key role in glucose homeostasis and appetite regulation by slowing gastric emptying and promoting satiety. By targeting the amylin receptor, VK3019 aims to provide a complementary mechanism to GLP-1 based therapies for weight loss. The drug is currently in Phase 1 clinical development, where it is being evaluated for safety, tolerability, and pharmacokinetics in healthy adults.

Targets

AMY3 (Amylin 3 receptor)CALCR (Calcitonin receptor)AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on VK3019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VK3019.